Spero Therapeutics Inc
Company Profile
Business description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Contact
675 Massachusetts Avenue
14th Floor
CambridgeMA02139
USAT: +1 857 242-1600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,820.30 | 6.40 | -0.07% |
| CAC 40 | 7,829.29 | 72.96 | -0.92% |
| DAX 40 | 24,255.31 | 201.50 | -0.82% |
| Dow JONES (US) | 44,371.51 | 279.13 | -0.63% |
| FTSE 100 | 8,941.12 | 34.54 | -0.38% |
| HKSE | 24,139.57 | 111.20 | 0.46% |
| NASDAQ | 20,585.53 | 45.14 | -0.22% |
| Nikkei 225 | 39,569.68 | 76.68 | -0.19% |
| NZX 50 Index | 12,686.68 | 73.52 | -0.58% |
| S&P 500 | 6,259.75 | 20.71 | -0.33% |
| S&P/ASX 200 | 8,580.10 | 9.10 | -0.11% |
| SSE Composite Index | 3,510.18 | 0.50 | 0.01% |